Live Breaking News & Updates on Milestone Pharmaceuticals Daily

Stay updated with breaking news from Milestone pharmaceuticals daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Forecasted to Post Q1 2023 Earnings of ($0.38) Per Share

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Rating) – Research analysts at Oppenheimer issued their Q1 2023 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a report released on Wednesday, April 12th. Oppenheimer analyst L. Gershell expects that the company will post earnings of ($0.38) per share for the quarter. Oppenheimer has a “Outperform” rating […] ....

United States , Milestone Pharmaceuticals Stock Performance , Envestnet Asset Management Inc , Institutional Trading Of Milestone Pharmaceuticals , Milestone Pharmaceuticals Inc , Delphia United States Inc , News Ratings For Milestone Pharmaceuticals Daily , Beta Wealth Group Inc , Milestone Pharmaceuticals Company Profile , Milestone Pharmaceuticals , Get Rating , Milestone Pharmaceutical , Wealth Group , Envestnet Asset Management , Milestone Pharmaceuticals Daily , Nasdaq Mist , Earnings Estimates , Oppenheimer Holdings Inc ,

Carrier Global (NYSE:CARR) Price Target Raised to $48.00 at Deutsche Bank Aktiengesellschaft

Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) had its price objective cut by Oppenheimer from $16.00 to $13.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have an outperform rating on the stock. Oppenheimer also issued estimates for Milestone Pharmaceuticals’ Q1 2023 earnings at ($0.38) EPS, Q2 2023 earnings […] ....

United States , News Ratings For Milestone Pharmaceuticals Daily , Delphia United States Inc , Milestone Pharmaceuticals , Milestone Pharmaceuticals Inc , Institutional Trading Of Milestone Pharmaceuticals , Envestnet Asset Management Inc , Milestone Pharmaceuticals Company Profile , Beta Wealth Group Inc , Milestone Pharmaceuticals Price Performance , Get Rating , Wealth Group , Envestnet Asset Management , Milestone Pharmaceuticals Daily , Nasdaq Mist , Lower Price Target , Oppenheimer Holdings Inc ,

Milestone Pharmaceuticals (NASDAQ:MIST) Price Target Cut to $13.00

Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) had its target price reduced by Oppenheimer from $16.00 to $13.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 253.26% from the company’s current price. Separately, […] ....

United States , Dimensional Fund Advisors , Milestone Pharmaceuticals Inc , Milestone Pharmaceuticals , Jpmorgan Chase Co , Institutional Trading Of Milestone Pharmaceuticals , Acadian Asset Management , News Ratings For Milestone Pharmaceuticals Daily , Milestone Pharmaceuticals Stock , America Corp , Get Rating , Asset Management , Fund Advisors , Milestone Pharmaceuticals Daily , Nasdaq Mist , Lower Price Target , Oppenheimer Holdings Inc ,

Oppenheimer Lowers Milestone Pharmaceuticals (NASDAQ:MIST) Price Target to $13.00

Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) had its price target cut by Oppenheimer from $16.00 to $13.00 in a note issued to investors on Wednesday, The Fly reports. Oppenheimer’s price objective would suggest a potential upside of 238.54% from the company’s previous close. Separately, HC Wainwright restated a “buy” rating and issued a $25.00 price […] ....

United States , Milestone Pharmaceuticals Price Performance , Milestone Pharmaceuticals Inc , Institutional Trading Of Milestone Pharmaceuticals , Milestone Pharmaceuticals Company Profile , Cubist Systematic Strategies , News Ratings For Milestone Pharmaceuticals Daily , Milestone Pharmaceuticals , Delphia United States Inc , Get Rating , Systematic Strategies , Gate Manager , Delphia United States , Milestone Pharmaceuticals Daily , Nasdaq Mist , Lower Price Target , Oppenheimer Holdings Inc ,

Milestone Pharmaceuticals (NASDAQ:MIST) Receives "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) in a research report sent to investors on Thursday, Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2026 earnings at $1.07 EPS and FY2027 earnings at $2.13 […] ....

United States , Hedge Funds Weigh In On Milestone Pharmaceuticals , News Ratings For Milestone Pharmaceuticals Daily , Milestone Pharmaceuticals , Beta Wealth Group Inc , Envestnet Asset Management Inc , Delphia United States Inc , Milestone Pharmaceuticals Stock Performance , Milestone Pharmaceuticals Inc , Get Rating , Milestone Pharmaceutical , Wealth Group , Envestnet Asset Management , Milestone Pharmaceuticals Daily , Nasdaq Mist , Reiterated Rating , Hc Wainwright ,